Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease
Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved..
Pan-betacoronavirus neutralizing antibodies may hold the key to developing broadly protective vaccines against novel pandemic coronaviruses and to more effectively respond to SARS-CoV-2 variants. The emergence of Omicron and subvariants of SARS-CoV-2 illustrates the limitations of solely targeting the receptor-binding domain (RBD) of the spike (S) protein. Here, we isolated a large panel of broadly neutralizing antibodies (bnAbs) from SARS-CoV-2 recovered-vaccinated donors, which targets a conserved S2 region in the betacoronavirus spike fusion machinery. Select bnAbs showed broad in vivo protection against all three deadly betacoronaviruses, SARS-CoV-1, SARS-CoV-2, and MERS-CoV, which have spilled over into humans in the past two decades. Structural studies of these bnAbs delineated the molecular basis for their broad reactivity and revealed common antibody features targetable by broad vaccination strategies. These bnAbs provide new insights and opportunities for antibody-based interventions and for developing pan-betacoronavirus vaccines.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:56 |
|---|---|
| Enthalten in: |
Immunity - 56(2023), 3 vom: 14. März, Seite 669-686.e7 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhou, Panpan [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 20.03.2023 Date Revised 01.07.2023 published: Print-Electronic UpdateOf: bioRxiv. 2022 Mar 07;:. - PMID 35291291 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.immuni.2023.02.005 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353950300 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353950300 | ||
| 003 | DE-627 | ||
| 005 | 20231226061151.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.immuni.2023.02.005 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1179.xml |
| 035 | |a (DE-627)NLM353950300 | ||
| 035 | |a (NLM)36889306 | ||
| 035 | |a (PII)S1074-7613(23)00079-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhou, Panpan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.03.2023 | ||
| 500 | |a Date Revised 01.07.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a UpdateOf: bioRxiv. 2022 Mar 07;:. - PMID 35291291 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a Pan-betacoronavirus neutralizing antibodies may hold the key to developing broadly protective vaccines against novel pandemic coronaviruses and to more effectively respond to SARS-CoV-2 variants. The emergence of Omicron and subvariants of SARS-CoV-2 illustrates the limitations of solely targeting the receptor-binding domain (RBD) of the spike (S) protein. Here, we isolated a large panel of broadly neutralizing antibodies (bnAbs) from SARS-CoV-2 recovered-vaccinated donors, which targets a conserved S2 region in the betacoronavirus spike fusion machinery. Select bnAbs showed broad in vivo protection against all three deadly betacoronaviruses, SARS-CoV-1, SARS-CoV-2, and MERS-CoV, which have spilled over into humans in the past two decades. Structural studies of these bnAbs delineated the molecular basis for their broad reactivity and revealed common antibody features targetable by broad vaccination strategies. These bnAbs provide new insights and opportunities for antibody-based interventions and for developing pan-betacoronavirus vaccines | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, U.S. Gov't, Non-P.H.S. | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a S2 stem-helix site | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a SARS-CoV-2 variants of concern | |
| 650 | 4 | |a broad coronavirus protection | |
| 650 | 4 | |a broadly neutralizing antibodies | |
| 650 | 4 | |a coronavirus spike | |
| 650 | 4 | |a coronaviruses | |
| 650 | 4 | |a pan-betacoronavirus vaccines | |
| 650 | 7 | |a Broadly Neutralizing Antibodies |2 NLM | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 700 | 1 | |a Song, Ge |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Hejun |e verfasserin |4 aut | |
| 700 | 1 | |a Yuan, Meng |e verfasserin |4 aut | |
| 700 | 1 | |a He, Wan-Ting |e verfasserin |4 aut | |
| 700 | 1 | |a Beutler, Nathan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Xueyong |e verfasserin |4 aut | |
| 700 | 1 | |a Tse, Longping V |e verfasserin |4 aut | |
| 700 | 1 | |a Martinez, David R |e verfasserin |4 aut | |
| 700 | 1 | |a Schäfer, Alexandra |e verfasserin |4 aut | |
| 700 | 1 | |a Anzanello, Fabio |e verfasserin |4 aut | |
| 700 | 1 | |a Yong, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Peng, Linghang |e verfasserin |4 aut | |
| 700 | 1 | |a Dueker, Katharina |e verfasserin |4 aut | |
| 700 | 1 | |a Musharrafieh, Rami |e verfasserin |4 aut | |
| 700 | 1 | |a Callaghan, Sean |e verfasserin |4 aut | |
| 700 | 1 | |a Capozzola, Tazio |e verfasserin |4 aut | |
| 700 | 1 | |a Limbo, Oliver |e verfasserin |4 aut | |
| 700 | 1 | |a Parren, Mara |e verfasserin |4 aut | |
| 700 | 1 | |a Garcia, Elijah |e verfasserin |4 aut | |
| 700 | 1 | |a Rawlings, Stephen A |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Davey M |e verfasserin |4 aut | |
| 700 | 1 | |a Nemazee, David |e verfasserin |4 aut | |
| 700 | 1 | |a Jardine, Joseph G |e verfasserin |4 aut | |
| 700 | 1 | |a Safonova, Yana |e verfasserin |4 aut | |
| 700 | 1 | |a Briney, Bryan |e verfasserin |4 aut | |
| 700 | 1 | |a Rogers, Thomas F |e verfasserin |4 aut | |
| 700 | 1 | |a Wilson, Ian A |e verfasserin |4 aut | |
| 700 | 1 | |a Baric, Ralph S |e verfasserin |4 aut | |
| 700 | 1 | |a Gralinski, Lisa E |e verfasserin |4 aut | |
| 700 | 1 | |a Burton, Dennis R |e verfasserin |4 aut | |
| 700 | 1 | |a Andrabi, Raiees |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Immunity |d 1994 |g 56(2023), 3 vom: 14. März, Seite 669-686.e7 |w (DE-627)NLM075097818 |x 1097-4180 |7 nnns |
| 773 | 1 | 8 | |g volume:56 |g year:2023 |g number:3 |g day:14 |g month:03 |g pages:669-686.e7 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.immuni.2023.02.005 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 56 |j 2023 |e 3 |b 14 |c 03 |h 669-686.e7 | ||